CSPG4 has been previously investigated as an immunotherapeutic target for CAR T cells, among others in melanoma and glioblastoma (16–19), and we also observed specific recognition in a panel of CSPG4+/HLA-C*07:01+ melanoma and glioblastoma cell lines. This evidence concerns the gene HLA-C and glioblastoma.